clinical trial · NCT07414992
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Bladder Urothelial CarcinomaStereotactic body radiotherapyCemiplimabCemiplimab and FianlimabRadical cystectomy
brief summary
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).
started
May 1, 2026
primary completion
Mar 1, 2028
completion
Mar 1, 2028
last updated
May 1, 2026
detailed description
Patients will be assigned to neoadjuvant SBRT and cemiplimab (Cohort 1) until Cohort 1 completes accrual and then enrollment for Cohort 2 will begin with those patients receiving neoadjuvant SBRT plus cemiplimab and fianlimab.
official title
Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol